The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma.
 
Sahil D. Doshi
No Relationships to Disclose
 
Nazli Dizman
Stock and Other Ownership Interests - Several pharmaceutical companies (I)
Consulting or Advisory Role - Vivreon Biosciences
 
Andrea Knezevic
Consulting or Advisory Role - ByHeart
 
Amina Touma
No Relationships to Disclose
 
Reza Alaghehbandan
No Relationships to Disclose
 
Yasser Ged
Consulting or Advisory Role - AVEO; BostonGene; Bristol Myers Squibb; Eisai; Exelixis; Targeted Oncology; Targeted Oncology
 
Moshe Chaim Ornstein
Consulting or Advisory Role - AVEO; Bristol Myers Squibb Foundation; Eisai; Exelixis; Merck; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Merck
Research Funding - Aravive (Inst); Astellas Medivation (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Exelixis; Merck; Pfizer
 
Andrew Warren Hahn
Honoraria - Binacea; Medscape
Consulting or Advisory Role - Eisai; Exelixis; Intellisphere; Janssen Scientific Affairs; Pfizer
Research Funding - Bayer; Eisai (Inst)
Travel, Accommodations, Expenses - Dava Oncology
 
Pavlos Msaouel
Honoraria - Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Axiom Healthcare Strategies
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Martin H Voss
Stock and Other Ownership Interests - CellGenix (I)
Consulting or Advisory Role - Affimed Therapeutics; AVEO; Eisai; Exelixis; Genentech; Merck; MicuRx Pharmaceuticals; Oncorena
Research Funding - Pfizer
(OPTIONAL) Uncompensated Relationships - Aravive; AstraZeneca; AstraZeneca; BMS; Genentech/Roche